BiotechTube
Home/Kyowa Hakko Kirin/Abdul Mullick
AM

Abdul Mullick

Representative Director, President and Chief Executive Officer

Kyowa Hakko Kirin

Roles

Representative Director, President and Chief Executive OfficeratKyowa Hakko Kirin
Representative Director, President and Chief Executive OfficeratKyowa Kirin

Therapeutic Areas

Bone & MineralHematologic MalignanciesRare Diseases

Kyowa Hakko Kirin Pipeline

DrugIndicationPhase
Crysvita (burosumab)X-Linked Hypophosphatemia (XLH), Tumor-Induced Osteomalacia (TIO)Marketed
Poteligeo (mogamulizumab)Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Leukemia/Lymphoma (ATL)Marketed
Libmeldy (atidarsagene autotemcel)Metachromatic Leukodystrophy (MLD)Marketed
Orchard HSC-GT ProgramsWiskott-Aldrich Syndrome, MPS-IH, Beta-ThalassemiaPhase 1/2
KW-6356Parkinson's DiseasePhase 3
KHK4083Atopic DermatitisPhase 3
KHK2455Ulcerative Colitis / Autoimmune DiseasesPhase 2
ASP2138 (KHK4008)Solid Tumors (CLDN18.2+)Phase 1/2

Leadership Team at Kyowa Hakko Kirin

MM
Masashi Miyamoto
Representative Director, Chairman of the Board
View full Kyowa Hakko Kirin profile